Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, acellular pertussis + inactivated poliovirus vaccine + haemophilus influenzae type b
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a combination vaccine that provides immunization against five serious childhood diseases: diphtheria (caused by Corynebacterium diphtheriae), tetanus (Clostridium tetani), pertussis or whooping cough (Bordetella pertussis), poliomyelitis (poliovirus types 1-3), and invasive disease caused by Haemophilus influenzae type b. The vaccine contains: - Diphtheria toxoid - Tetanus toxoid - Acellular pertussis antigens - Inactivated poliovirus types 1–3 - Haemophilus influenzae type b polysaccharide conjugated to a carrier protein It works by stimulating the immune system to produce antibodies against these pathogens without causing disease. It is administered intramuscularly as a four-dose series for children aged 6 weeks through 4 years. This combination reduces the number of injections required for full protection[2][4][5][6].
- Brand names
- PentacelPediacelInfanrix IPV + HibPentaxim
- Other names
- diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus B conjugate vaccine
02
Targets
PV3 (Sabin) (Poliovirus type 3 antigen)Diphtheria toxin
Beyond the preview
Go deeper on diphtheria, tetanus, acellular pertussis + inactivated poliovirus vaccine + haemophilus influenzae type b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, acellular pertussis + inactivated poliovirus vaccine + haemophilus influenzae type b.